The next-generation FLT3 inhibitor crenolanib is a promising novel agent [17] currently under evaluation in phase 3 randomized trials for patients with R/R [18] and ND FLT3-mutant AML [19]. The gene discussed is FLT3; the disease is acute myeloid leukemia.